Sugi Predict

Sugi Predict / Targets / MAK

MAK

Serine/threonine-protein kinase MAK · P20794 · MAK on Sugi Atlas →

1,803 patent compounds predicted against MAK, 1,470 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Pha-665752 Pha-665752 (SCHEMBL93654) 1.00 1/20
Pha-665752 Pha-665752 (SCHEMBL93655) 1.00 1/20
Pha-665752 Pha-665752 (SCHEMBL93656) 1.00 1/20
Pha-665752 Pha-665752 (SCHEMBL93657) 1.00 1/20
Pha-665752 Pha-665752 (SCHEMBL140412) 1.00 1/20
Bms-387032 Bms-387032 (SCHEMBL187401) 1.00 1/20
Rg-547 Rg-547 (SCHEMBL2397067) 1.00 1/20
SCHEMBL143795 SCHEMBL143795 0.93 1/20
SCHEMBL3522526 SCHEMBL3522526 0.91 1/20
SCHEMBL3522463 SCHEMBL3522463 0.89 1/20
SCHEMBL145952 SCHEMBL145952 0.88 1/20
SCHEMBL144319 SCHEMBL144319 0.88 1/20
SCHEMBL146729 SCHEMBL146729 0.88 1/20
SCHEMBL144256 SCHEMBL144256 0.88 1/20
SCHEMBL4350447 SCHEMBL4350447 0.87 1/20
SCHEMBL143939 SCHEMBL143939 0.87 1/20
SCHEMBL147210 SCHEMBL147210 0.87 1/20
SCHEMBL148118 SCHEMBL148118 0.87 1/20
SCHEMBL144589 SCHEMBL144589 0.86 1/20
SCHEMBL145804 SCHEMBL145804 0.86 1/20

Clinical trials — most relevant to MAK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor PHASE2ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs PHASE2ACTIVE_NOT_RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
ERK Inhibitor JSI-1187 in Advanced Solid Tumors PHASE1UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Hypotaurine Supplementation Benefits in Cryopreservation nanCOMPLETED
Expression of EPK in Recurrent Miscarriage nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAK binder may also engage these)

ProteinNameSimilarity
Q9JKV2 — 1.000 Q9JKV2 →
P20793 — 1.000 P20793 →
Q04859 — 1.000 Q04859 →
Q62726 — 0.999 Q62726 →
Q501Q9 — 0.996 Q501Q9 →
P23293 — 0.996 P23293 →
Q9TTK0 — 0.995 Q9TTK0 →
P14680 — 0.995 P14680 →
CILK1 Serine/threonine-protein kinase ICK 0.995 landscape →
CDKL5 Cyclin-dependent kinase-like 5 0.994 landscape →
B3WFY8 — 0.994 B3WFY8 →
Q9Y7W4 — 0.994 Q9Y7W4 →
G5EDB2 — 0.994 G5EDB2 →
B2GUY1 — 0.994 B2GUY1 →
A8X4H1 — 0.994 A8X4H1 →
Q6FKC6 — 0.993 Q6FKC6 →
Q6CRA9 — 0.993 Q6CRA9 →
Q6L5D4 — 0.993 Q6L5D4 →
Q75D46 — 0.993 Q75D46 →
Q6FQ83 — 0.993 Q6FQ83 →
Q753D9 — 0.993 Q753D9 →
Q8RX66 — 0.993 Q8RX66 →
Q4R8T9 — 0.993 Q4R8T9 →
Q8BLF2 — 0.993 Q8BLF2 →
Q12152 — 0.993 Q12152 →
Q6PAD2 — 0.993 Q6PAD2 →
Q4R7T5 — 0.992 Q4R7T5 →
Q8MSG8 — 0.992 Q8MSG8 →
Q9SJG9 — 0.992 Q9SJG9 →
Q3UTQ8 — 0.992 Q3UTQ8 →